RMD Stock Recent News
RMD LATEST HEADLINES
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Boris Schlossberg, BK Asset Management, joins 'Power Lunch' to discuss SoFi, Warner Bros. Discovery and ResMed.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.
ResMed topped consensus Wall Street revenue and earnings estimates with its fiscal Q2 results. The company delivered double-digit-percentage growth across all of its products and services.
ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.66 per share a year ago.
ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.
Google “How important is sleep?” and you get three billion results.